Diabetes Increases IBD Infection Risk

Article

Patients with inflammatory bowel diseases are sometimes treated with immunosuppressive drugs, particularly if they have a significant co-morbidity. A Boston team of researchers found that when that co-morbidity is diabetes, patients are at greater risk of coming down with infections.

Patients with inflammatory bowel diseases are sometimes treated with immunosuppressive drugs, particularly if they have a significant co-morbidity.

A Boston team of researchers found that when that co-morbidity is diabetes, patients are at greater risk of coming down with infections.

In an abstract presented May 16 at the Digestive Disease Week 2015 conference in Washington, DC, Ashwin Ananthakrishnan, MD, and colleagues at Massachusetts General Hospital in Boston, MA, and colleagues at other Boston-based institutions looked at 2,766 patients who received at least 1 prescription for immunomodulators. Of those 210 patients developed an infectious complication within a year of the first prescription.

These patients were likely to be older (46 yrs. vs. 41 years) female (58% vs. 52%) and have 1 or more additional co-morbidity.

They were also more likely to have received a prescription for steroids (62% vs. 31%).

Nineteen percent of patients who developed an infection had diabetes. Only 8% of those who did not become infected had diabetes.

The most common infections in both groups were sepsis, pneumonia, cellulitis, and urinary tract infections.

Diabetes was independently associated with a nearly 2-fold increase in risk of infections are adjusting for age, other co-morbidities, and medication.

“Counseling and monitoring for such risks in addition to ensuring appropriate prophylaxis against preventable infections may help improve patient outcomes,” the researchers concluded.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.